Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prasinezumab in Early Parkinson's Disease
NCT03100149Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Jun 2017
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of prasinezumab in Parkinson's disease (PD), sponsored by Roche. Started Jun 2017; status: active, not recruiting.
02
Drugs
prasinezumab
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03100149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03100149.